CRISPR and Pain Management Innovations

This chapter focuses on the recent approval of a novel non-opioid pain medication by Vertex, examining its unique pricing model and potential impact on the opioid crisis. It also discusses the challenges faced by CRISPR companies amidst market skepticism, exploring the balance between scientific advancement and investor expectations. The conversation covers regulatory dynamics in gene editing, contrasting CRISPR with RNA therapies, and the uncertain future of these technologies.